Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Awakn Life Sciences Corp (OP: AWKNF ) 0.0908 UNCHANGED Last Price Updated: 1:41 PM EDT, Aug 12, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Awakn Life Sciences Corp < Previous 1 2 3 4 5 Next > Awakn And Catalent's Partnership Could Provide Hope For People Suffering From Addiction September 26, 2022 Since 2020, Awakn Life Sciences Corp. (OTCQB: AWKNF) reports that it has been researching, developing and commercializing therapeu Via Benzinga Psychedelic Stocks Continue To Plummet: -16% This Week; -33% MTD; Now -57% YTD September 25, 2022 Look at how the only psychedelic stocks with market caps larger than $50M gave performed this last week. Via Talk Markets 8 Largest Psychedelic Stocks Continued Their Decline Last Week September 18, 2022 The 8 stocks in the munKNEE Psychedelic Compounds-Based Drug Stocks Index were collectively down 10% in the past week. We also take a look at some therapy-clinic stocks. Via Talk Markets Awakn Shares Its Q2 2022 Results, Showing Consistent Growth On Its Second Full Financial Year September 17, 2022 Biotech firm leading the Alcohol Use Disorder (AUD) treatment Awakn Life Sciences Corp. (OTCQB: AWKNF) has announced its financial outcomes and business highlights for the three months ended July 31,... Via Benzinga Psychedelics Companies Are Teaming Up To Offer Access Veterans September 13, 2022 Two psychedelics companies have announced they’ll be collaborating to offer ketamine infusions in the US and psilocybin clinical retreats internationally with a special focus on access needs for... Via Benzinga Psychedelics Companies Seek Innovative Methods To Deliver Assisted Therapies, This One Stands Out September 12, 2022 As competence grows, biopharmaceuticals are searching for ways to present their specific psychedelic substance-assisted therapies in a way that might differentiate them from their competitors while... Via Benzinga Battling With Booze? Here's A Deeper Look At Ketamine for Alcohol Use Disorder September 10, 2022 This article by Elisabetta Fato was originally published on Microdose and appears here with permission. In the last decades, there has been a growing interest in psychedelics for the treatment of mood... Via Benzinga Most, But Not All, Psychedelics Companies Have Sufficient Liquidity September 06, 2022 The Chart represents the liquidity positions of the 21 Psychedelic sector companies in the Viridian Value Tracker database. Via Benzinga World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them August 30, 2022 The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business... Via Benzinga There Could Be More Hope For Alcohol Addicts As This Company Enters U.S. Addiction Treatment And Relapse Prevention Market August 19, 2022 For people suffering from any type of addiction, getting the best medical care can make a significant difference in their journey to recovery. In the case of alcohol abuse, for example, the talk about... Via Benzinga Awakn's Second Licensing Partnership Agreement In A Week, This Time In Canada: Ketamine For Pain Comorbidities August 18, 2022 Psychedelics therapeutics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed what constitutes its first licensing partnership deal in Canada. Via Benzinga Awakn Enters U.S. Addiction Treatment & Relapse Prevention Market With Ketamine Therapy For Alcohol Use Disorder August 16, 2022 Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company focused on addiction treatments, has signed a licensing partnership agreement with US ketamine therapy clinics owner Revitalist Lifestyle... Via Benzinga Phase 3 Trial On Ketamine Therapy Gets Almost $2M From UK State Funding July 20, 2022 Biotech psychedelics company Awakn Life Sciences Corp. (OTCQB: AWKNF) has been granted funding for 66% of the costs from its phase 3 clinical trial on Via Benzinga Awakn Life Sciences Receives Funding From UK Government To Identify Most Efficient Go-To-Market Pathway For Proprietary Ketamine-Assisted Therapy July 18, 2022 Awakn Life Sciences Corp. (OTCQB: AWKNF) reported it secured funding from Innovate UK to identify the quickest and most cost-effective route to market in both the U.K. and the U.S. Via Benzinga Awakn Life Sciences: Business And Corporate Update For Psychedelics Biotech July 15, 2022 Biotech psychedelics company Awakn Life Sciences Corp. (OTCQB: AWKNF) has just published its business and corporate updates. Via Benzinga Michael Pollan's 'How To Change Your Mind' Now On Netflix, Here Are Reactions From Experts July 14, 2022 Michael Pollan's 2018 book “How To Change Your Mind: What the science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence” is available on Netflix (NASDAQ:... Via Benzinga UK To Fund Development Of Awakn's Ketamine-Assisted Therapy Program For Alcohol Use Disorder In US And UK July 05, 2022 Biotech therapeutics company Awakn Life Sciences Corp. Via Benzinga Michael Pollan's 'How To Change Your Mind' Coming Soon To Netflix: Documentary Based On Psychedelics Best Seller June 17, 2022 The freshest news traversing many of the major institutions, researchers' and activists’ accounts on Twitter is the recent release of a docu-series based on writer Michael Pollan’s 2018 book “How To... Via Benzinga These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry June 02, 2022 In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its... Via Benzinga Psyched: Medical Psychedelics In Davos, Canadian Sen Does Psychedelics, Ei.Ventures & Mycotopia To Merge Into $383M Company May 24, 2022 Medical Psychedelics have made it into Davos, just in time for the World Economic Forum. Via Benzinga Awakn Life Sciences Reports Completing World's First Ketamine Study For A Range Of Behavioral Addictions May 24, 2022 Photo by Tranava University on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Could Ketamine be a... Via Benzinga Awakn's Study On Psychedelics For Treating Addiction Shows Promise, Will Undertake Broader Research May 19, 2022 Awakn Life Sciences (OTCQB: AWKNF) has announced the successful completion of the first ketamine study for a varied set of behavioral addictions. Via Benzinga Wake-Up Call: This Biotech Company Is Using Psychedelics To Treat Addiction May 05, 2022 This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Via Benzinga Core One Labs Begins Trading On OTCQB April 06, 2022 Under the CLABF symbol, psychedelics-oriented company Core One Labs (OTCQB: CLABF) started trading on the OTCQB Venture ... Via Benzinga Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More! April 06, 2022 It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector. Via Benzinga Stifel Initiates Coverage On Awakn Life Sciences With A Speculative Buy, $8 Target Price Target April 04, 2022 Awakn Life Sciences (OTC: AWKNF) is in the news after a respected analyst has upgraded the stock. Awakn is a publicly traded company which trades on the over-the-counter market with the symbol of Via Benzinga This Biotech Company Is Landing Ketamine-Assisted Therapy In England's Capital March 31, 2022 This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. As it pushes ahead with expansion into the United States,... Via Benzinga Awakn Life Sciences Seeks To Treat Addictions: Gambling, Binge Eating And Compulsive Sexual Behavior March 28, 2022 Awakn Life Sciences (OTC: AWKNF) is not only going after alcoholism but also binge eating disorder, compulsive sexual behavior and even Internet gaming disorder. Via Benzinga This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction March 24, 2022 Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Via Benzinga Psychedelic And Cannabis Drug Stocks Continue Advance February 13, 2022 This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses. Via Talk Markets < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.